Immunofluorescence assay is a powerful technique used to analyze the distribution of glycans, proteins, and small biological and non-biological molecules (cells and tissues) using antibodies conjugated with a fluorescent dye, known as fluorophore, which can be visualized using a fluorescence microscope or imaging systems.
How much is the Immunofluorescence Assay Market worth?
The immunofluorescence assay market is expected to reach USD 2.01 Billion by 2023 from USD 1.43 Billion in 2017, at a CAGR of 5.8%. The increasing prevalence of chronic diseases, increasing R&D spending, and increasing healthcare spending are the major factors driving the growth of the market.
“By product, the reagents segment accounted for the largest share of the immunofluorescence assay market in 2017.”
On the basis of product, the reagents segment accounted for the largest share of the global immunofluorescence assay market. The large share of this segment is due to growing applications of biosciences and biotechnology within the pharmaceutical and healthcare fields, the rising prevalence of a number of diseases, growing R&D activities, and government initiatives to strengthen national research capabilities are driving the growth of the reagents segment.
Download PDF Brochure @
“The cancer segment holds the largest share in 2017”
Based on disease, the cancer segment accounted for the largest share of the immunofluorescence assay market. The large share of this segment can be attributed to the fact that the increasing prevalence of cancer across the globe and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer.
“By type, the indirect immunofluorescence segment held the largest market share of the immunofluorescence assay market in 2017”
Based on type, the immunofluorescence assay is segmented into direct and indirect immunofluorescence. The indirect immunofluorescence assay accounted for the major share of the immunofluorescence assay market. The advantages of indirect immunofluorescence technique such as its sensitivity, flexibility, better amplification of the signal, and lower cost—over direct immunofluorescence is the key factor increasing the adoption of this technique.
“By end user, the pharmaceutical and biotechnology companies segment held the largest market share of the immunofluorescence market in 2017”
Based on end user, the pharmaceutical and biotechnology companies segment accounted for the largest share of the immunofluorescence assay market. Factors contributing to its largest share include the increasing use of immunofluorescence assay in the study of various diseases and drug discovery & development processes in pharmaceutical and biotechnology companies.
Request for Sample Pages @
North America to dominate the market in 2017
This report covers the market across four major geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Of the four geographic regions studied in the report, North America accounted for the largest share of this market majorly due to the rising incidence of chronic & infectious diseases, increasing R&D spending, increasing research activities, favorable government funding opportunities.
Geographically, the global market is segmented into North America, Europe, Asia Pacific, and Rest of the World. In 2017, North America accounted for the largest share of the market, followed by Europe and Asia Pacific.
The major players in the market include Thermo Fisher (US), Inova Diagnostics (US), Bio-Rad (US), Abcam (UK), PerkinELmer (US), Merck Millipore (US), Cell Signaling Technology (US), MEDIPAN GMBH (Germany), Sino Biological (China), Danaher (US), and Vector Laboratories (US).
For More Information @ https://www.marketsandmarkets.com/PressReleases/immunofluorescence-assay.asp